[go: up one dir, main page]

TR200202169T1 - Tanı ve tedavide kullanım için pürifiye hepatit C virüsü zarf proteinleri. - Google Patents

Tanı ve tedavide kullanım için pürifiye hepatit C virüsü zarf proteinleri.

Info

Publication number
TR200202169T1
TR200202169T1 TR2002/02169T TR200202169T TR200202169T1 TR 200202169 T1 TR200202169 T1 TR 200202169T1 TR 2002/02169 T TR2002/02169 T TR 2002/02169T TR 200202169 T TR200202169 T TR 200202169T TR 200202169 T1 TR200202169 T1 TR 200202169T1
Authority
TR
Turkey
Prior art keywords
diagnosis
treatment
envelope proteins
virus envelope
purified hepatitis
Prior art date
Application number
TR2002/02169T
Other languages
English (en)
Inventor
Maertens Geert
Bosman Fons
Depla Erik
Original Assignee
Innogenetics N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics N.V. filed Critical Innogenetics N.V.
Publication of TR200202169T1 publication Critical patent/TR200202169T1/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Koruyucu bir asi bilesimi olup, özelligi asagidakileri içermesidir: bir E1 proteini, bir E2 proteini ve bu E1 ve E2 proteinlerinin paarçalari arasindan seçilen en bir pürifiye HCV tekli veya spesifik oligomerik rekombinant zarf proteininden koruyucu olarak etkili bir miktar ile istege bagli olarak farmasötik açidan kabul edilebilir bir adjuvan.
TR2002/02169T 2001-01-11 2002-01-11 Tanı ve tedavide kullanım için pürifiye hepatit C virüsü zarf proteinleri. TR200202169T1 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26066901P 2001-01-11 2001-01-11
US31576801P 2001-08-30 2001-08-30

Publications (1)

Publication Number Publication Date
TR200202169T1 true TR200202169T1 (tr) 2004-06-21

Family

ID=26948130

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/02169T TR200202169T1 (tr) 2001-01-11 2002-01-11 Tanı ve tedavide kullanım için pürifiye hepatit C virüsü zarf proteinleri.

Country Status (16)

Country Link
EP (1) EP1463753A2 (tr)
KR (1) KR20020089371A (tr)
CN (1) CN1547588A (tr)
AR (1) AR032240A1 (tr)
AU (1) AU2002238502B2 (tr)
BR (1) BR0203518A (tr)
CA (1) CA2400643A1 (tr)
CZ (1) CZ20032164A3 (tr)
HU (1) HUP0302416A2 (tr)
IL (1) IL151033A0 (tr)
MX (1) MXPA02008886A (tr)
NO (1) NO20024325L (tr)
PL (1) PL363175A1 (tr)
RU (1) RU2313363C2 (tr)
TR (1) TR200202169T1 (tr)
WO (1) WO2002055548A2 (tr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2274643C2 (ru) 2001-04-24 2006-04-20 Иннодженетикс Н.В. Выделенный оболочечный белок hcv, способ его получения и лекарство, вакцина, фармацевтическая композиция (варианты) его содержащие
JP2006516955A (ja) * 2002-11-08 2006-07-13 イノジェネティックス・ナムローゼ・フェンノートシャップ Ｅ１ペプチド及びｎｓ３ペプチドを含むｈｃｖワクチン組成物
EP1561470A1 (en) * 2003-06-20 2005-08-10 Innogenetics N.V. HCV vaccines comprising the envelope-1 (E1) protein or the corresponding DNA and at least one antiviral agent
EP2062590A1 (en) * 2003-09-22 2009-05-27 Green Peptide Co., Ltd. Peptide derived from Hepatitis C virus
CN100365124C (zh) * 2005-10-27 2008-01-30 云南大学 一段丙型肝炎病毒特异性cDNA序列的应用
CN115980352A (zh) * 2022-12-30 2023-04-18 宁波博肽生物技术有限公司 一种hcv抗原包被预处理剂、抗原包被方法及检测试剂盒

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721505B2 (en) * 1994-07-29 2006-05-10 Innogenetics N.V. Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use

Also Published As

Publication number Publication date
WO2002055548A3 (en) 2004-08-05
IL151033A0 (en) 2003-04-10
NO20024325L (no) 2002-11-11
WO2002055548A8 (en) 2002-10-31
PL363175A1 (en) 2004-11-15
AU2002238502B2 (en) 2007-09-06
MXPA02008886A (es) 2003-04-25
RU2002121632A (ru) 2004-03-20
NO20024325D0 (no) 2002-09-10
AR032240A1 (es) 2003-10-29
WO2002055548A2 (en) 2002-07-18
CN1547588A (zh) 2004-11-17
BR0203518A (pt) 2002-12-17
CZ20032164A3 (cs) 2003-10-15
AU2002238502A1 (en) 2002-07-24
RU2313363C2 (ru) 2007-12-27
EP1463753A2 (en) 2004-10-06
HUP0302416A2 (hu) 2003-10-28
AU2002238502B9 (en) 2002-07-24
KR20020089371A (ko) 2002-11-29
CA2400643A1 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
DK1090033T3 (da) Partikler af HCV-kappeproteiner: Anvendelse til vaccination
DK1296711T3 (da) HPV-E7 til behandling af humant papillomavirus
EA200201279A1 (ru) Способы и композиции для лечения вирусного гепатита c
HUP9901186A2 (hu) Peptid-és adjuvánsalapú gyógyszerkészítmény immunmodulációra
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
DK1255815T3 (da) Porcint reproduktivt og respiratorisk syndromvirus til fremgangsmåder til anvendelse
ATE371373T1 (de) Durch polynukleinsäuren vom reproduktiven und respiratorischen syndromvirus des schweines kodierte proteine
AR042378A2 (es) Poxvirus recombinante de mapache, vacuna para uso en gatos y uso de dicho poxvirus para preparar una vacuna eficaz contra la infeccion del virus de inmunodeficiencia felina
MY141594A (en) 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
NZ518999A (en) Vaccine compositions
TR200202169T1 (tr) Tanı ve tedavide kullanım için pürifiye hepatit C virüsü zarf proteinleri.
SE9903031D0 (sv) Peptide mixture and vaccine against a chronic viral infection
MY141459A (en) Recombinant anti-idiotypic antibodies
EP0868522A4 (en) RECOMBINANT POX VIRUS OF INFECTIOUS PERITONITIS OF THE CAT, COMPOSITIONS THEREOF AND METHODS FOR THE PRODUCTION AND USE
DE69533067D1 (de) Hepatis e-virus antigene und dessen verwendungen
DE69011122D1 (de) Rubella-e1 und c peptide.
IL141443A0 (en) Vaccine comprising cytokine-induced heat shock proteins (hsp)
EA200702079A1 (ru) Вакцина
FR2724385B1 (fr) Vaccin de la peritonite infectieuse feline.
ATE409705T1 (de) Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs
WO2002089733A3 (en) Recombinant orf2 proteins of the swine hepatitis e virus and their use as a vaccine and as a diagnostic reagent for medical and veterinary applications
DE602004028512D1 (de) Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon
AU6839598A (en) Antigenic structural peptide, antigenic and immunogenic compounds and uses for detecting, preventing and treating an hcv infection
NO20042124L (no) Thymosinforsterkning ved genetisk immunisering
ES2105984A1 (es) Adenovirus recombinantes que expresan antigenos del virus de la gastroenteritis porcina transmisible (vgpt) y su empleo en la formacion de vacunas.